In an oncology trial, what is a seamless Phase II/III design and what is a typical benefit?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

In an oncology trial, what is a seamless Phase II/III design and what is a typical benefit?

A seamless Phase II/III design is an adaptive, single trial that combines what would traditionally be two separate studies into one ongoing protocol. It starts with multiple treatment arms and uses prespecified interim analyses to identify which arms are showing promise and which are not. Ineffective arms can be dropped, and patients are reallocated to the more promising arms, with the trial continuing into the confirmatory phase under the same framework. The typical benefit is that development can move faster and be more efficient. By stopping futile arms early, fewer patients are exposed to ineffective therapies, and resources are concentrated on the most promising options, which can shorten the time to a regulatory decision and potentially reduce the overall number of patients needed compared with running separate Phase II and Phase III trials. Two separate trials with no data sharing miss the seamless, data-driven transition between phases. Stopping early for futility without reallocating patients ignores the adaptive efficiency, and a non-randomized observational design isn’t a randomized seamless trial at all.

A seamless Phase II/III design is an adaptive, single trial that combines what would traditionally be two separate studies into one ongoing protocol. It starts with multiple treatment arms and uses prespecified interim analyses to identify which arms are showing promise and which are not. Ineffective arms can be dropped, and patients are reallocated to the more promising arms, with the trial continuing into the confirmatory phase under the same framework.

The typical benefit is that development can move faster and be more efficient. By stopping futile arms early, fewer patients are exposed to ineffective therapies, and resources are concentrated on the most promising options, which can shorten the time to a regulatory decision and potentially reduce the overall number of patients needed compared with running separate Phase II and Phase III trials.

Two separate trials with no data sharing miss the seamless, data-driven transition between phases. Stopping early for futility without reallocating patients ignores the adaptive efficiency, and a non-randomized observational design isn’t a randomized seamless trial at all.

More practice questions